Gene editing startup Metagenomi finally sets IPO range, as preclinical biotech eyes $87M

Kyle LaHucik

Senior Reporter

Gene editing company Metagenomi has set a price range for its proposed initial public offering, marking a key step for preclinical biotechs after weeks of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gene editing startup Metagenomi finally sets IPO range, as preclinical biotech eyes $87M

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Gene edit­ing start­up Metageno­mi fi­nal­ly sets IPO range, as pre­clin­i­cal biotech eyes $87M

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Gene editing startup Metagenomi finally sets IPO range, as preclinical biotech eyes $87M

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials